Roche’s foray into personalized healthcare software for cancer patients advanced with a recent Accenture data integration deal. The partnership (PDF) is for Roche’s physician support tool, the Navify Tumor Board solution, that aggregates patient data across multiple sources.
Roche launched the digital cancer patient workflow solution last October to help cancer care teams gather and organize information to evaluate treatment options for an individual patient with data collected digitally across multiple sources. While traditional tumor boards meet in person, Navify also allows for remote participation.
“Oncology care teams are now able to collaborate on the review of patient cases and tailor treatments to the individual with a higher degree of confidence and more efficiently,” said Roche Diagnostics CEO Roland Diggelman said, in a news release at the launch.
Accenture’s data integration role, added late last month, will help information glow seamlessly and allow data compatibility between hospitals and others on the team while operating on a secure cloud platform.
Tumor boards, also known as oncology patient management conferences, are changing both with the addition of digitized patient data and the move to genetically tailored cancer therapies. The boards have evolved “from general case meetings into weekly focused gatherings on cancers affecting specific organs, ‘mini-tumor boards,’ and even molecular tumor boards,” according to a Roche white paper.
Roche is beginning to roll out Navify—free trials are still available on its web site—and is currently available in the U.S., U.K., Germany, Spain, Sweden, Switzerland and the Netherlands.
“To take full advantage of the solution, it needs to be integrated into the hospital setting and that is part of what Accenture will be doing,” said Andrea Brückner, who leads Accenture’s Life Sciences practice in Europe, adding that the company is excited to be collaborating with Roche on Navify to “hopefully make a difference in patients’ lives.”
Roche markets cancer treatments include checkpoint inhibitor Tecentriq, lung cancer drug Alecensa for ALK-positive patients and recently approved hemophilia therapy Hemlibra. Tecentriq was recently boosted by positive results from its first-line lung-cancer combo trial, although questions on some specifics remain.